This topic contains a solution. Click here to go to the answer

Author Question: Relative to a perfectly competitive market, as long as the monopolist does not benefit from ... (Read 33 times)

melina_rosy

  • Hero Member
  • *****
  • Posts: 531
Relative to a perfectly competitive market, as long as the monopolist does not benefit from substantial economies of scale,
 a. price and quantity are higher under monopoly
  b. price and quantity are lower under monopoly
  c. quantity is higher and price is lower under monopoly
  d. quantity is lower and price is higher under monopoly
  e. there are no differences in price and quantity

Question 2

What act of Congress declared restraint of trade illegal and declared any attempt at monopolizing unlawful?
 a. the Celler-Kefauver Anti-Merger Act
  b. the Sherman Antitrust Act
  c. the Clayton Act
  d. the Wheeler-Lea Act
  e. the Clayton-Celler Act



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

lauravaras

  • Sr. Member
  • ****
  • Posts: 347
Answer to Question 1

D

Answer to Question 2

B





 

Did you know?

Drugs are in development that may cure asthma and hay fever once and for all. They target leukotrienes, which are known to cause tightening of the air passages in the lungs and increase mucus productions in nasal passages.

Did you know?

The highest suicide rate in the United States is among people ages 65 years and older. Almost 15% of people in this age group commit suicide every year.

Did you know?

More than 30% of American adults, and about 12% of children utilize health care approaches that were developed outside of conventional medicine.

Did you know?

About 80% of major fungal systemic infections are due to Candida albicans. Another form, Candida peritonitis, occurs most often in postoperative patients. A rare disease, Candida meningitis, may follow leukemia, kidney transplant, other immunosuppressed factors, or when suffering from Candida septicemia.

Did you know?

The Food and Drug Administration has approved Risperdal, an adult antipsychotic drug, for the symptomatic treatment of irritability in children and adolescents with autism. The approval is the first for the use of a drug to treat behaviors associated with autism in children. These behaviors are included under the general heading of irritability and include aggression, deliberate self-injury, and temper tantrums.

For a complete list of videos, visit our video library